Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.75 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.69 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9808816 | 0.89 | HDAC8 (0.71) | SRD5A2FFAR1KEAP1ALDH1A1HDAC3 | |
| SCHEMBL7889494 | 0.87 | ALDH1A1 (0.67) | SRD5A2FFAR1ALDH1A1HDAC1SMN1; SMN2 | |
| SCHEMBL28208994 | 0.87 | MAPT (0.70) | SRD5A2FFAR1KEAP1HDAC3MAPK1 | |
| SCHEMBL1744622 | 0.86 | FFAR1 (0.80) | SRD5A2FFAR1FFAR4ALDH1A1SMN1; SMN2 | |
| SCHEMBL7898126 | 0.85 | ALDH1A1 (0.64) | SRD5A2FFAR1KEAP1ALDH1A1HDAC1 | |
| SCHEMBL11132309 | 0.85 | SRD5A2 (0.61) | SRD5A2FFAR1KEAP1FFAR4HDAC3 | |
| SCHEMBL9715721 | 0.85 | FFAR1 (0.66) | SRD5A2FFAR1KEAP1FFAR4HDAC3 | |
| SCHEMBL11138168 | 0.85 | ALDH1A1 (0.71) | SRD5A2FFAR1KEAP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3112767 | 0.83 | KEAP1 (0.62) | SRD5A2FFAR1KEAP1FFAR4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11132121 | 0.83 | SRD5A2 (0.59) | SRD5A2FFAR1KEAP1FFAR4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032453-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2025-01-30 | — | — | US | disclosed |
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2024-02-08 | — | — | US | disclosed |
| US-20240016947-A1 | METHOD FOR CONJUGATING ANTIBODY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE | NOVELTY NOBILITY INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | ILLUMINA, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | ILLUMINA, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11723984-B2 | Method for conjugating antibody and physiologically active substance | NOVELTY NOBILITY INC. (KR) | 2023-08-15 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | SANTOLECAN PHARMACEUTICALS LLC | 2021-07-29 | — | — | US | disclosed |
| US-20080312092-A1 | Photoinduced Signal Amplification Through Externally Sensitized Photofragmentation in Masked Photosensitizers | THE UNIVERSITY OF DENVER | 2008-12-18 | — | — | US | disclosed |
| WO-2007008472-A2 | PHOTOINDUCED SIGNAL AMPLIFICATION THROUGH EXTERNALLY SENSITIZED PHOTOFRAGMENTATION IN MASKED PHOTOSENSITIZERS | COLORADO SEMINARY, WHICH OWNS AND OPERATES THE UNIVERSITY OF DENVER (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | disclosed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | disclosed |
| US-4937375-A | (Phenylethenyl)phenylpropionic acid and its ester, and method for producing (benzoylphenyl)propionic acid or its ester | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1990-06-26 | — | — | US | disclosed |
| EP-0283038-A1 | (Vinylphenyl)phenylmethane and method for producing (benzoylphenyl)propionic acid | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016947-A1 | METHOD FOR CONJUGATING ANTIBODY AND PHYSIOLOGICALLY ACTIVE SUBSTANCE | DNPEP, SHBG, ANPEP | SRD5A2 3960/4885FFAR1 2737/4885KEAP1 4606/4885 |
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | SRD5A2 540/4885FFAR1 20/4885KEAP1 2256/4885 |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | DDOST, UGT2B17, UGT1A7 | SRD5A2 1632/4885FFAR1 1687/4885KEAP1 526/4885 |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | TENT4A, TENT4B, DNTT | SRD5A2 4737/4885FFAR1 4750/4885KEAP1 3134/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | SRD5A2 1843/4885FFAR1 3198/4885KEAP1 896/4885 |
| US-20250032453-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | SRD5A2 540/4885FFAR1 20/4885KEAP1 2256/4885 |
| US-11723984-B2 | Method for conjugating antibody and physiologically active substance | DNPEP, ANPEP, PTMS | SRD5A2 3410/4885FFAR1 2269/4885KEAP1 4367/4885 |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | GPR55, GPR65, GPR35 | SRD5A2 540/4885FFAR1 20/4885KEAP1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.